Protalix BioTherapeutics, Inc. (PLX) Stock

Protalix BioTherapeutics, Inc. (PLX) is a Healthcare stock trading at $2.37 (as of 2026-08-21), with a market capitalization of $190.55M and a trailing P/E of 10.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins using its ProCellEx plant cell-based expression system, with operations in the United States and other international markets. It offers Elelyso for Gaucher disease and has product candidates including PRX-102, PRX-110, PRX-115, and PRX-119.

Understand Protalix BioTherapeutics, Inc.: how it makes money

Protalix BioTherapeutics develops and commercializes recombinant therapeutic proteins using its proprietary ProCellEx plant cell expression system, and it earns money from selling its approved product (Elelyso) and potentially from license and research and development services.

The profit engine is the commercial value of recombinant therapies produced with its ProCellEx platform, where near term revenue depends on selling Elelyso, and upside depends on pipeline programs progressing through late-stage clinical development, with license and R&D services as an additional revenue source.

Revenue by segment (latest quarter)
Goods	$0.0B
License R&D	$0.0B

Business quality (Strong): Data provided is partial on how revenue is split across businesses, overall revenue is reported as 0.0B (with small goods revenue at 0.01B), but the clinical trial operating metrics are specific.

Valuation: At 12× earnings, PLX trades 28% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

Has a commercial therapy: Elelyso is offered for the treatment of Gaucher disease.
Pipeline includes late-stage development: PRX-102 is in the last stage of clinical trials for the treatment of Fabry diseases.
Platform is the core technology: Its recombinant therapeutic proteins are based on its proprietary ProCellEx plant cell-based protein expression system.

Bear case

Revenue is minimal in the latest quarter: Revenue is reported as 0.0B for the quarter ended 2026-03-31, with very small selling goods revenue at 0.01B in the provided segment candidates.
Clinical development carries safety and outcome risk: In the provided clinical snapshot, subjects with drug-related adverse events (rate) are 25.0 percent, which can affect development and regulatory outcomes.
Material value depends on future clinical progress: Key pipeline assets such as PRX-102 and PRX-110 still rely on clinical and development timelines rather than being fully commercialized in the provided facts.

Valuation — source: SEC EDGAR (first-party)
Price	$2.37
Market Cap	$190.55M
P/E Ratio	10.1
EV / EBITDA	6.6
Price / Book	2.67
Price / Sales	2.36
FCF Yield	0.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$52.74M
Net Margin	-12.5%
Revenue Growth (YoY)	27.1%
FCF Growth (YoY)	94.1%

Financial Health — source: SEC EDGAR
Altman Z-Score	-2.19 (distress)

Valuation vs Sector & Industry
Stock P/E	10.1
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2
vs Sector	-53.7%
vs Industry	-41.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($7.85M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Dror Bashan
Employees	213
Country	US
IPO Date	1998-05-15

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.